Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 354

1.

Serum Concentrations of p-Cresyl Sulfate and Indoxyl Sulfate, but Not Inflammatory Markers, Increase in Incident Peritoneal Dialysis Patients in Parallel with Loss of Residual Renal Function.

Viaene L, Meijers BK, Vanrenterghem Y, Evenepoel P.

Perit Dial Int. 2015 Jul-Aug;35(4):492. doi: 10.3747/pdi.2015.00095. No abstract available.

2.

Time course of asymmetric dimethylarginine and symmetric dimethylarginine levels after successful renal transplantation.

Claes KJ, Bammens B, Kuypers DR, Meijers B, Naesens M, Sprangers B, Vanrenterghem Y, Lerut E, de Loor H, Evenepoel P.

Nephrol Dial Transplant. 2014 Oct;29(10):1965-72. doi: 10.1093/ndt/gfu219.

3.

Postimplantation X-ray parameters predict functional catheter problems in peritoneal dialysis.

Bammens B, Peeters D, Jaekers J, Claes KJ, Evenepoel P, Kuypers D, Meijers B, Naesens M, Vanrenterghem Y, Monbaliu D.

Kidney Int. 2014 Nov;86(5):1001-6. doi: 10.1038/ki.2014.203.

PMID:
24940799
4.

Intrarenal resistive index after renal transplantation.

Naesens M, Heylen L, Lerut E, Claes K, De Wever L, Claus F, Oyen R, Kuypers D, Evenepoel P, Bammens B, Sprangers B, Meijers B, Pirenne J, Monbaliu D, de Jonge H, Metalidis C, De Vusser K, Vanrenterghem Y.

N Engl J Med. 2013 Nov 7;369(19):1797-806. doi: 10.1056/NEJMoa1301064.

5.
6.

Post-streptococcal glomerulonephritis: not an extinct disease!

Demuynck M, Lerut E, Kuypers D, Evenepoel P, Claes K, Naesens M, Meijers B, Vanrenterghem Y, Bammens B.

Acta Clin Belg. 2013 May-Jun;68(3):215-7.

PMID:
24156223
7.

Long-term exposure to belatacept in recipients of extended criteria donor kidneys.

Charpentier B, Medina Pestana JO, Del C Rial M, Rostaing L, Grinyó J, Vanrenterghem Y, Matas A, Zhang R, Mühlbacher F, Pupim L, Florman S.

Am J Transplant. 2013 Nov;13(11):2884-91. doi: 10.1111/ajt.12459.

8.

Impact of CYP3A5 genotype on tacrolimus versus midazolam clearance in renal transplant recipients: new insights in CYP3A5-mediated drug metabolism.

de Jonge H, de Loor H, Verbeke K, Vanrenterghem Y, Kuypers DR.

Pharmacogenomics. 2013 Sep;14(12):1467-80. doi: 10.2217/pgs.13.133.

PMID:
24024898
9.

The predictive value of kidney allograft baseline biopsies for long-term graft survival.

De Vusser K, Lerut E, Kuypers D, Vanrenterghem Y, Jochmans I, Monbaliu D, Pirenne J, Naesens M.

J Am Soc Nephrol. 2013 Nov;24(11):1913-23. doi: 10.1681/ASN.2012111081.

10.

Aortic calcifications and arterial stiffness as predictors of cardiovascular events in incident renal transplant recipients.

Claes KJ, Heye S, Bammens B, Kuypers DR, Meijers B, Naesens M, Vanrenterghem Y, Evenepoel P.

Transpl Int. 2013 Oct;26(10):973-81. doi: 10.1111/tri.12151.

11.

Renal clearance and intestinal generation of p-cresyl sulfate and indoxyl sulfate in CKD.

Poesen R, Viaene L, Verbeke K, Claes K, Bammens B, Sprangers B, Naesens M, Vanrenterghem Y, Kuypers D, Evenepoel P, Meijers B.

Clin J Am Soc Nephrol. 2013 Sep;8(9):1508-14. doi: 10.2215/CJN.00300113.

12.

Reasons for dose reduction of mycophenolate mofetil during the first year after renal transplantation and its impact on graft outcome.

Vanhove T, Kuypers D, Claes KJ, Evenepoel P, Meijers B, Naesens M, Vanrenterghem Y, Cornelis T, Bammens B.

Transpl Int. 2013 Aug;26(8):813-21. doi: 10.1111/tri.12133.

13.

Combined kidney and intestinal transplantation in patients with enteric hyperoxaluria secondary to short bowel syndrome.

Ceulemans LJ, Nijs Y, Nuytens F, De Hertogh G, Claes K, Bammens B, Naesens M, Evenepoel P, Kuypers D, Vanrenterghem Y, Monbaliu D, Pirenne J.

Am J Transplant. 2013 Jul;13(7):1910-4. doi: 10.1111/ajt.12305.

14.

Improved adherence to tacrolimus once-daily formulation in renal recipients: a randomized controlled trial using electronic monitoring.

Kuypers DR, Peeters PC, Sennesael JJ, Kianda MN, Vrijens B, Kristanto P, Dobbels F, Vanrenterghem Y, Kanaan N; ADMIRAD Study Team..

Transplantation. 2013 Jan 27;95(2):333-40. doi: 10.1097/TP.0b013e3182725532.

PMID:
23263559
15.

Renal cell carcinoma in the allograft: what is the role of polyomavirus?

Neirynck V, Claes K, Naesens M, De Wever L, Pirenne J, Kuypers D, Vanrenterghem Y, Poppel HV, Kabanda A, Lerut E.

Case Rep Nephrol Urol. 2012 Jul;2(2):125-34. doi: 10.1159/000341917.

16.

Chronic histological damage in early indication biopsies is an independent risk factor for late renal allograft failure.

Naesens M, Kuypers DR, De Vusser K, Vanrenterghem Y, Evenepoel P, Claes K, Bammens B, Meijers B, Lerut E.

Am J Transplant. 2013 Jan;13(1):86-99. doi: 10.1111/j.1600-6143.2012.04304.x.

17.

In vivo CYP3A4 activity, CYP3A5 genotype, and hematocrit predict tacrolimus dose requirements and clearance in renal transplant patients.

de Jonge H, de Loor H, Verbeke K, Vanrenterghem Y, Kuypers DR.

Clin Pharmacol Ther. 2012 Sep;92(3):366-75. doi: 10.1038/clpt.2012.109.

PMID:
22871995
18.

A multicenter, randomized, double-blind study comparing different FK778 doses (manitimus) with tacrolimus and steroids vs. MMF with tacrolimus and steroids in renal transplantation.

Wlodarczyk Z, Vanrenterghem Y, Krämer BK, Squifflet JP, Ostrowski M.

BMC Nephrol. 2012 Jul 26;13:68. doi: 10.1186/1471-2369-13-68.

19.

Evidence in favor of a severely impaired net intestinal calcium absorption in patients with (early-stage) chronic kidney disease.

Viaene L, Meijers BK, Vanrenterghem Y, Evenepoel P.

Am J Nephrol. 2012;35(5):434-41. doi: 10.1159/000338299.

PMID:
22538635
20.

Daytime rhythm and treatment-related fluctuations of serum phosphorus concentration in dialysis patients.

Viaene L, Meijers B, Vanrenterghem Y, Evenepoel P.

Am J Nephrol. 2012;35(3):242-8. doi: 10.1159/000336308.

PMID:
22353750
Items per page

Supplemental Content

Loading ...
Support Center